We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Read MoreHide Full Article
Key Takeaways
NTLA's MAGNITUDE studies for ATTR were placed on FDA hold after rare liver enzyme elevations.
Intellia is assessing the issue with regulators and has paused nex-z milestone guidance.
NTLA expects mid-2026 HAELO data and eyes a 2026 BLA filing for lonvo-z amid rising uncertainty.
Intellia Therapeutics (NTLA - Free Report) is currently advancing two late-stage in vivo pipeline candidates – nex-z (or, NTLA-2001) for transthyretin (ATTR) amyloidosis and lonvo-z (or, NTLA-2002) for hereditary angioedema (HAE).
Intellia is developing nex-z, in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) . Nex-z is being evaluated in two late-stage studies, MAGNITUDE and MAGNITUDE-2, for ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTR amyloidosis with polyneuropathy (ATTRv-PN), respectively.
While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. The collaboration with REGN for nex-z is a boost for Intellia, as it provides the latter with resources to support the development of the candidate.
Last month, the FDA placed a clinical hold on NTLA’s phase III MAGNITUDE and MAGNITUDE-2 studies for ATTR-CM and ATTRv-PN, respectively. So far, Grade 4 liver enzyme elevations have been observed in under 1% of the MAGNITUDE study patients and none in the MAGNITUDE-2 study.
As 2026 approaches, Intellia is working with investigators and regulators to understand the issue and develop additional risk-mitigation strategies. With the clinical hold in place, Intellia has suspended its milestone guidance for nex-z and will provide an update once a regulatory path forward is established.
Intellia is developing another in vivo candidate, lonvo-z, for the treatment of HAE. The company completed enrolling HAE patients in the pivotal phase III HAELO study evaluating lonvo-z in September 2025 and now expects to share top-line data by mid-2026.
The company remains on track to submit a potential biologics license application for NTLA-2002 in HAE in the second half of 2026.
However, the regulatory setback faced in the case of nex-z has cast a doubt on the outlook for lonvo-z. This makes NTLA’s HAE study outcome, to be reported next year, increasingly important for its near-term success heading into 2026.
NTLA's Competition in the Target Market
While Intellia’s pipeline of innovative CRISPR-based therapies looks promising, the development of these remains a complex affair. Upon successful development and potential approval, the candidates are likely to face stiff competition from companies that are also using the CRISPR/Cas9 gene editing technology to address various diseases in specific areas.
CRISPR Therapeutics (CRSP - Free Report) is the first and only company in the world to market a CRISPR/Cas9-based therapy. The company’s one-shot gene therapy, Casgevy, was approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
CRSP has developed Casgevy in partnership with large biotech, Vertex Pharmaceuticals, which is responsible for the therapy’s global development and commercialization. Vertex recorded $61.5 million in Casgevy revenues in the first nine months of 2025.
Meanwhile, Beam Therapeutics (BEAM - Free Report) is developing its genome-editing candidate, BEAM-101, in the phase I/II BEACON study for treating SCD.
Beam Therapeutics is also developing in vivo therapies in early- to mid-stage studies targeting AATD-associated liver disease and glycogen storage disease Ia indications.
NTLA's Price Performance, Valuation and Estimates
Year to date, shares of Intellia have plunged 25.6% against the industry’s rise of 15.4%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Intellia is trading at a discount to the industry. Going by the price/book ratio, the company’s shares currently trade at 1.24, lower than 3.65 for the industry. The stock is trading below its five-year mean of 3.01.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intellia’s 2025 loss per share has narrowed from $4.14 to $4.00 over the past 30 days. Loss per share estimates for 2026 have also narrowed from $4.10 to $3.61 during the same time frame.
Image: Bigstock
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Key Takeaways
Intellia Therapeutics (NTLA - Free Report) is currently advancing two late-stage in vivo pipeline candidates – nex-z (or, NTLA-2001) for transthyretin (ATTR) amyloidosis and lonvo-z (or, NTLA-2002) for hereditary angioedema (HAE).
Intellia is developing nex-z, in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) . Nex-z is being evaluated in two late-stage studies, MAGNITUDE and MAGNITUDE-2, for ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTR amyloidosis with polyneuropathy (ATTRv-PN), respectively.
While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. The collaboration with REGN for nex-z is a boost for Intellia, as it provides the latter with resources to support the development of the candidate.
Last month, the FDA placed a clinical hold on NTLA’s phase III MAGNITUDE and MAGNITUDE-2 studies for ATTR-CM and ATTRv-PN, respectively. So far, Grade 4 liver enzyme elevations have been observed in under 1% of the MAGNITUDE study patients and none in the MAGNITUDE-2 study.
As 2026 approaches, Intellia is working with investigators and regulators to understand the issue and develop additional risk-mitigation strategies. With the clinical hold in place, Intellia has suspended its milestone guidance for nex-z and will provide an update once a regulatory path forward is established.
Intellia is developing another in vivo candidate, lonvo-z, for the treatment of HAE. The company completed enrolling HAE patients in the pivotal phase III HAELO study evaluating lonvo-z in September 2025 and now expects to share top-line data by mid-2026.
The company remains on track to submit a potential biologics license application for NTLA-2002 in HAE in the second half of 2026.
However, the regulatory setback faced in the case of nex-z has cast a doubt on the outlook for lonvo-z. This makes NTLA’s HAE study outcome, to be reported next year, increasingly important for its near-term success heading into 2026.
NTLA's Competition in the Target Market
While Intellia’s pipeline of innovative CRISPR-based therapies looks promising, the development of these remains a complex affair. Upon successful development and potential approval, the candidates are likely to face stiff competition from companies that are also using the CRISPR/Cas9 gene editing technology to address various diseases in specific areas.
CRISPR Therapeutics (CRSP - Free Report) is the first and only company in the world to market a CRISPR/Cas9-based therapy. The company’s one-shot gene therapy, Casgevy, was approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
CRSP has developed Casgevy in partnership with large biotech, Vertex Pharmaceuticals, which is responsible for the therapy’s global development and commercialization. Vertex recorded $61.5 million in Casgevy revenues in the first nine months of 2025.
Meanwhile, Beam Therapeutics (BEAM - Free Report) is developing its genome-editing candidate, BEAM-101, in the phase I/II BEACON study for treating SCD.
Beam Therapeutics is also developing in vivo therapies in early- to mid-stage studies targeting AATD-associated liver disease and glycogen storage disease Ia indications.
NTLA's Price Performance, Valuation and Estimates
Year to date, shares of Intellia have plunged 25.6% against the industry’s rise of 15.4%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Intellia is trading at a discount to the industry. Going by the price/book ratio, the company’s shares currently trade at 1.24, lower than 3.65 for the industry. The stock is trading below its five-year mean of 3.01.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intellia’s 2025 loss per share has narrowed from $4.14 to $4.00 over the past 30 days. Loss per share estimates for 2026 have also narrowed from $4.10 to $3.61 during the same time frame.
Image Source: Zacks Investment Research
NTLA's Zacks Rank
Intellia currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.